Commonwealth of Massachusetts
MassHealth Drug Utilization Review Program
P.O. Box 2586, Worcester, MA 01613-2586
Fax: (877) 208-7428 **Phone:** (800) 745-7318

Gonadotropin-Releasing Hormone Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Member information

Last name ______________________________ First name ____________________________ MI __________

MassHealth member ID # _________________ Date of birth ____

Gender (Check one.) ☐ F ☐ M Member's place of residence ☐ home ☐ nursing facility

Medication information

Medication requested

☐ Eligard (leuprolide)
☐ Firmagon (degarelix)
☐ Lupaneta Pack (leuprolide/norethindrone)
☐ Lupron (leuprolide)
☐ Orilissa (elagolix)
☐ Supprelin LA (histrelin)
☐ Synarel (nafarelin)
☐ Trelstar (triptorelin)
☐ Triptodur (triptorelin)
☐ Vantas (histrelin)
☐ Zoladex (goserelin)

Dose, frequency, and duration of medication requested ____

Indication (Check all that apply.)

☐ Advanced breast cancer
☐ Advanced prostate cancer
☐ Endometrial thinning prior to ablation for abnormal uterine bleeding
☐ Endometriosis
☐ Idiopathic or neurogenic central precocious puberty (CPP)
☐ Uterine leiomyomata (fibroids)
☐ Other ____________________________________

Please indicate whether the request is for pharmacy or in-office billing. ☐ Pharmacy billing ☐ In-office billing

Section I. Please complete for requests for idiopathic or neurogenic CPP.

1. Provide age of secondary sex characteristics onset. ____
2. Is the member under the care of a pediatric endocrinologist?
   ☐ Yes. Name of member's pediatric endocrinologist ____________________ Date of last visit ___________
   ☐ No. Please attach medical records of a consultation with a pediatric endocrinologist.
3. For Triptodur, has the member tried Lupron and experienced an adverse reaction or inadequate response?
   ☐ Yes. Please provide date and outcome for trial.
   Date(s) ___________________________________ Outcome(s) ________________________________
   ☐ No. Please explain. ____

Section II. Please complete for requests for endometriosis.

1. Has the member tried non-steroidal anti-inflammatory drugs (NSAIDs) and experienced an adverse reaction or inadequate response?
   ☐ Yes. Provide drug names, dates, and outcomes for trials below.
   Drug name(s) ____________ Date(s) ____________ Outcome(s) ____________
   ☐ No. Please explain if there is a contraindication to this trial. ____________
2. Has the member tried hormonal contraceptives and experienced an adverse reaction or inadequate response?
   ☐ Yes. Provide drug names, dates, and outcomes for trials below.
   Drug name(s) ____________ Date(s) ____________ Outcome(s) ____________
   ☐ No. Please explain if there is a contraindication to this trial. ____________
3. For Orilissa, has the member tried Lupron and experienced an adverse reaction or inadequate response?
   ☐ Yes. Please provide date and outcome for trial.
   Date(s) ____________ Outcome(s) ____________
   ☐ No. Please explain if there is a contraindication to this trial. ____________

Section III. Please complete for requests for endometrial thinning prior to ablation for abnormal uterine bleeding and uterine leiomyomata (fibroids).

Is surgery planned?

☐ Yes. Please provide anticipated date of surgery. ____________

☐ No. Please explain. ____________

Section IV. Please complete for all other diagnoses, excluding advanced breast cancer and advanced prostate cancer.

Please describe the medical necessity for the use of gonadotropin-releasing hormone, including previous trials and outcomes.

____

____

____

Section V. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

____

____

Prescriber information

Last name* ____________ First name* ____________ MI ____________

NPI* ____________ Individual MH Provider ID ____________

DEA No. ____________ Office Contact Name ____________

Address ____________ City ____________ State ____________ Zip ____________

E-mail address ____________

Telephone No.* ____________ Fax No.* ____________

** Required*

over

Prescribing provider’s attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider’s signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

Signature required ____

Printed name of prescribing provider ________________________________ Date __________________________